Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could stop scalp scarring and hair loss

NCT ID NCT07532603

Disease control Sponsor: Priovant Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study tests an oral medication called brepocitinib for adults with lichen planopilaris, a condition that causes scalp inflammation, scarring, and hair loss. About 342 participants will receive either the drug or a placebo to see if it reduces symptoms and improves scalp appearance. The goal is to find a treatment that controls the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 342 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Scalp biopsy consistent with LPP 3. Active and symptomatic LPP at screening and baseline- 4. Weight \> 40 kg to \< 130 kg with BMI ≤ 45 kg/m2 Exclusion Criteria: 1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer). 2. High risk of thrombosis or cardiovascular disease 3. High risk of herpes zoster 4. Active or recent infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lichen planopilaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lichen planopilaris lichen planus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lichen planopilaris

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    61 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Trial Site

    RECRUITING

    Birmingham, Alabama, 35244, United States

  • Clinical Trial Site

    RECRUITING

    Phoenix, Arizona, 85006, United States

  • Clinical Trial Site

    RECRUITING

    Scottsdale, Arizona, 85259, United States

  • Clinical Trial Site

    RECRUITING

    Irvine, California, 92617, United States

  • Clinical Trial Site

    RECRUITING

    Oakland, California, 94611, United States

  • Clinical Trial Site

    RECRUITING

    Sacramento, California, 95823, United States

  • Clinical Trial Site

    RECRUITING

    San Francisco, California, 94115, United States

  • Clinical Trial Site

    RECRUITING

    Denver, Colorado, 80237, United States

  • Clinical Trial Site

    RECRUITING

    Farmington, Connecticut, 06032, United States

  • Clinical Trial Site

    RECRUITING

    New Haven, Connecticut, 06519, United States

  • Clinical Trial Site

    RECRUITING

    Miami, Florida, 33136, United States

  • Clinical Trial Site

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Clinical Trial Site

    RECRUITING

    Skokie, Illinois, 60077, United States

  • Clinical Trial Site

    RECRUITING

    Clarksville, Indiana, 47129, United States

  • Clinical Trial Site

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Clinical Trial Site

    RECRUITING

    Leawood, Kansas, 66211, United States

  • Clinical Trial Site

    RECRUITING

    Louisville, Kentucky, 40241, United States

  • Clinical Trial Site

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Clinical Trial Site

    RECRUITING

    Burlington, Massachusetts, 01805, United States

  • Clinical Trial Site

    RECRUITING

    Ann Arbor, Michigan, 48103, United States

  • Clinical Trial Site

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Clinical Trial Site

    RECRUITING

    Medina, Minnesota, 55340, United States

  • Clinical Trial Site

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Clinical Trial Site

    RECRUITING

    Kansas City, Missouri, 66103, United States

  • Clinical Trial Site

    RECRUITING

    Lee's Summit, Missouri, 64064, United States

  • Clinical Trial Site

    RECRUITING

    Lebanon, New Hampshire, 03766, United States

  • Clinical Trial Site

    RECRUITING

    New Hyde Park, New York, 11042, United States

  • Clinical Trial Site

    RECRUITING

    New York, New York, 10451, United States

  • Clinical Trial Site

    RECRUITING

    Durham, North Carolina, 27713, United States

  • Clinical Trial Site

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Clinical Trial Site

    RECRUITING

    Columbus, Ohio, 43213, United States

  • Clinical Trial Site

    RECRUITING

    Medina, Ohio, 44256, United States

  • Clinical Trial Site

    RECRUITING

    Portland, Oregon, 97210, United States

  • Clinical Trial Site

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Clinical Trial Site

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • Clinical Trial Site

    RECRUITING

    Murfreesboro, Tennessee, 37128, United States

  • Clinical Trial Site

    RECRUITING

    Smyrna, Tennessee, 37167, United States

  • Clinical Trial Site

    RECRUITING

    Austin, Texas, 78613, United States

  • Clinical Trial Site

    RECRUITING

    Austin, Texas, 78660, United States

  • Clinical Trial Site

    RECRUITING

    Cedar Park, Texas, 78613, United States

  • Clinical Trial Site

    RECRUITING

    Prosper, Texas, 75078, United States

  • Clinical Trial Site

    RECRUITING

    Tyler, Texas, 75703, United States

  • Clinical Trial Site

    RECRUITING

    Murray, Utah, 84107, United States

  • Clinical Trial Site

    RECRUITING

    Norfolk, Virginia, 23502, United States

  • Clinical Trial Site

    RECRUITING

    Richmond, Virginia, 23235, United States

  • Clinical Trial Site

    RECRUITING

    Roanoke, Virginia, 24016, United States

  • Clinical Trial Site

    RECRUITING

    Mill Creek, Washington, 98012, United States

  • Clinical Trial Site

    RECRUITING

    Adelaide, 5074, Australia

  • Clinical Trial Site

    RECRUITING

    Perth, 6018, Australia

  • Clinical Trial Site

    RECRUITING

    Sydney, 2217, Australia

  • Clinical Trial Site

    RECRUITING

    Edmonton, Alberta, T6G1C3, Canada

  • Clinical Trial Site

    RECRUITING

    Guelph, Ontario, N1L0B7, Canada

  • Clinical Trial Site

    RECRUITING

    London, Ontario, M5M3Z8, Canada

  • Clinical Trial Site

    RECRUITING

    Toronto, Ontario, L4B1A5, Canada

  • Clinical Trial Site

    RECRUITING

    Toronto, Ontario, N6H5L4, Canada

  • Clinical Trial Site

    RECRUITING

    Salford, Manchester, M68HD, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Glasgow, Scotland, G312ER, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Brighton, BN21ES, United Kingdom

  • Clinical Trial Site

    RECRUITING

    London, SE19RT, United Kingdom

  • Clinical Trial Site

    RECRUITING

    London, SW109NH, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Wrexham, LL7YP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.